2022-09-012023-08-312023-08-31false11531430A NEW BEGINNING THERAPIES LIMITED2023-10-0986900iso4217:GBPxbrli:pure115314302022-09-01115314302023-08-31115314302022-09-012023-08-31115314302021-09-01115314302022-08-31115314302021-09-012022-08-3111531430bus:SmallEntities2022-09-012023-08-3111531430bus:AuditExempt-NoAccountantsReport2022-09-012023-08-3111531430bus:AbridgedAccounts2022-09-012023-08-3111531430bus:PrivateLimitedCompanyLtd2022-09-012023-08-3111531430core:WithinOneYear2023-08-3111531430core:AfterOneYear2023-08-3111531430core:WithinOneYear2022-08-3111531430core:AfterOneYear2022-08-3111531430core:ShareCapital2023-08-3111531430core:SharePremium2023-08-3111531430core:RevaluationReserve2023-08-3111531430core:OtherReservesSubtotal2023-08-3111531430core:RetainedEarningsAccumulatedLosses2023-08-3111531430core:ShareCapital2022-08-3111531430core:SharePremium2022-08-3111531430core:RevaluationReserve2022-08-3111531430core:OtherReservesSubtotal2022-08-3111531430core:RetainedEarningsAccumulatedLosses2022-08-3111531430core:LandBuildings2023-08-3111531430core:PlantMachinery2023-08-3111531430core:Vehicles2023-08-3111531430core:FurnitureFittings2023-08-3111531430core:OfficeEquipment2023-08-3111531430core:NetGoodwill2023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-08-3111531430core:ListedExchangeTraded2023-08-3111531430core:UnlistedNon-exchangeTraded2023-08-3111531430core:LandBuildings2022-08-3111531430core:PlantMachinery2022-08-3111531430core:Vehicles2022-08-3111531430core:FurnitureFittings2022-08-3111531430core:OfficeEquipment2022-08-3111531430core:NetGoodwill2022-08-3111531430core:IntangibleAssetsOtherThanGoodwill2022-08-3111531430core:ListedExchangeTraded2022-08-3111531430core:UnlistedNon-exchangeTraded2022-08-3111531430core:LandBuildings2022-09-012023-08-3111531430core:PlantMachinery2022-09-012023-08-3111531430core:Vehicles2022-09-012023-08-3111531430core:FurnitureFittings2022-09-012023-08-3111531430core:OfficeEquipment2022-09-012023-08-3111531430core:NetGoodwill2022-09-012023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3111531430core:ListedExchangeTraded2022-09-012023-08-3111531430core:UnlistedNon-exchangeTraded2022-09-012023-08-3111531430core:MoreThanFiveYears2022-09-012023-08-3111531430core:Non-currentFinancialInstruments2023-08-3111531430core:Non-currentFinancialInstruments2022-08-3111531430dpl:CostSales2022-09-012023-08-3111531430dpl:DistributionCosts2022-09-012023-08-3111531430dpl:AdministrativeExpenses2022-09-012023-08-3111531430core:LandBuildings2022-09-012023-08-3111531430core:PlantMachinery2022-09-012023-08-3111531430core:Vehicles2022-09-012023-08-3111531430core:FurnitureFittings2022-09-012023-08-3111531430core:OfficeEquipment2022-09-012023-08-3111531430core:NetGoodwill2022-09-012023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2022-09-012023-08-3111531430dpl:GroupUndertakings2022-09-012023-08-3111531430dpl:ParticipatingInterests2022-09-012023-08-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2022-09-012023-08-3111531430core:ListedExchangeTraded2022-09-012023-08-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-09-012023-08-3111531430core:UnlistedNon-exchangeTraded2022-09-012023-08-3111531430dpl:CostSales2021-09-012022-08-3111531430dpl:DistributionCosts2021-09-012022-08-3111531430dpl:AdministrativeExpenses2021-09-012022-08-3111531430core:LandBuildings2021-09-012022-08-3111531430core:PlantMachinery2021-09-012022-08-3111531430core:Vehicles2021-09-012022-08-3111531430core:FurnitureFittings2021-09-012022-08-3111531430core:OfficeEquipment2021-09-012022-08-3111531430core:NetGoodwill2021-09-012022-08-3111531430core:IntangibleAssetsOtherThanGoodwill2021-09-012022-08-3111531430dpl:GroupUndertakings2021-09-012022-08-3111531430dpl:ParticipatingInterests2021-09-012022-08-3111531430dpl:GroupUndertakingscore:ListedExchangeTraded2021-09-012022-08-3111531430core:ListedExchangeTraded2021-09-012022-08-3111531430dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-09-012022-08-3111531430core:UnlistedNon-exchangeTraded2021-09-012022-08-3111531430core:NetGoodwill2023-08-3111531430core:IntangibleAssetsOtherThanGoodwill2023-08-3111531430core:LandBuildings2023-08-3111531430core:PlantMachinery2023-08-3111531430core:Vehicles2023-08-3111531430core:FurnitureFittings2023-08-3111531430core:OfficeEquipment2023-08-3111531430core:AfterOneYear2023-08-3111531430core:WithinOneYear2023-08-3111531430core:ListedExchangeTraded2023-08-3111531430core:UnlistedNon-exchangeTraded2023-08-3111531430core:ShareCapital2023-08-3111531430core:SharePremium2023-08-3111531430core:RevaluationReserve2023-08-3111531430core:OtherReservesSubtotal2023-08-3111531430core:RetainedEarningsAccumulatedLosses2023-08-3111531430core:NetGoodwill2022-08-3111531430core:IntangibleAssetsOtherThanGoodwill2022-08-3111531430core:LandBuildings2022-08-3111531430core:PlantMachinery2022-08-3111531430core:Vehicles2022-08-3111531430core:FurnitureFittings2022-08-3111531430core:OfficeEquipment2022-08-3111531430core:AfterOneYear2022-08-3111531430core:WithinOneYear2022-08-3111531430core:ListedExchangeTraded2022-08-3111531430core:UnlistedNon-exchangeTraded2022-08-3111531430core:ShareCapital2022-08-3111531430core:SharePremium2022-08-3111531430core:RevaluationReserve2022-08-3111531430core:OtherReservesSubtotal2022-08-3111531430core:RetainedEarningsAccumulatedLosses2022-08-3111531430core:NetGoodwill2021-09-0111531430core:IntangibleAssetsOtherThanGoodwill2021-09-0111531430core:LandBuildings2021-09-0111531430core:PlantMachinery2021-09-0111531430core:Vehicles2021-09-0111531430core:FurnitureFittings2021-09-0111531430core:OfficeEquipment2021-09-0111531430core:AfterOneYear2021-09-0111531430core:WithinOneYear2021-09-0111531430core:ListedExchangeTraded2021-09-0111531430core:UnlistedNon-exchangeTraded2021-09-0111531430core:ShareCapital2021-09-0111531430core:SharePremium2021-09-0111531430core:RevaluationReserve2021-09-0111531430core:OtherReservesSubtotal2021-09-0111531430core:RetainedEarningsAccumulatedLosses2021-09-0111531430core:AfterOneYear2022-09-012023-08-3111531430core:WithinOneYear2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-09-012023-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2023-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-08-3111531430core:Non-currentFinancialInstrumentscore:CostValuation2022-08-3111531430core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-08-3111531430core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-08-3111531430bus:Director12022-09-012023-08-3111531430bus:Director22022-09-012023-08-31

A NEW BEGINNING THERAPIES LIMITED

Registered Number
11531430
(England and Wales)

Unaudited Financial Statements for the Year ended
31 August 2023

A NEW BEGINNING THERAPIES LIMITED
Company Information
for the year from 1 September 2022 to 31 August 2023

Directors

ADAMS, Scott Nicholas
WEYMES, Amanda Jane

Registered Address

134 Bricknell Avenue
Hull
HU5 4QQ

Registered Number

11531430 (England and Wales)
A NEW BEGINNING THERAPIES LIMITED
Statement of Financial Position
31 August 2023

Notes

2023

2022

£

£

£

£

Fixed assets
Tangible assets69981,084
9981,084
Current assets
Debtors6,6515,251
Cash at bank and on hand46,08156,393
52,73261,644
Prepayments and accrued income1,0233,065
Creditors amounts falling due within one year8(27,920)(34,559)
Net current assets (liabilities)25,83530,150
Total assets less current liabilities26,83331,234
Creditors amounts falling due after one year9(20,363)(29,017)
Net assets6,4702,217
Capital and reserves
Called up share capital22
Profit and loss account6,4682,215
Shareholders' funds6,4702,217
The financial statements were approved and authorised for issue by the Board of Directors on 9 October 2023, and are signed on its behalf by:
ADAMS, Scott Nicholas
Director
WEYMES, Amanda Jane
Director

Registered Company No. 11531430
A NEW BEGINNING THERAPIES LIMITED
Notes to the Financial Statements
for the year ended 31 August 2023

1.Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
2.Compliance with applicable reporting framework
The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.
3.Basis of measurement used in financial statements
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
4.Accounting policies
Functional and presentation currency policy
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Property, plant and equipment policy
Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:

Straight line (years)
Fixtures and fittings4
Revenue recognition policy
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Taxation policy
Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax policy
Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Employee benefits policy
Contributions to defined contribution plans are expensed in the period to which they relate.
5.Employee information
The average number of persons employed by the company during the year amounted tO

20232022
Average number of employees during the year22
6.Property, plant and equipment

Total

£
Cost or valuation
At 01 September 224,043
Additions290
At 31 August 234,333
Depreciation and impairment
At 01 September 222,959
Charge for year376
At 31 August 233,335
Net book value
At 31 August 23998
At 31 August 221,084
7.Debtors within one year

2023

2022

££
Trade debtors / trade receivables6,6405,250
Other debtors111
Total6,6515,251
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
8.Creditors within one year

2023

2022

££
Trade creditors / trade payables3,9554,550
Bank borrowings and overdrafts9,6619,726
Taxation and social security10,87614,647
Accrued liabilities and deferred income3,4285,636
Total27,92034,559
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
9.Creditors after one year

2023

2022

££
Bank borrowings and overdrafts20,36329,017
Total20,36329,017